FDA Approved: EGATEN — Original Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved EGATEN (triclabendazole) under an original NDA from Novartis Pharmaceuticals Corporation. The approval is for the treatment of fascioliasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fascioliasis

Drugs mentioned

• Egaten (triclabendazole)

Snippet

ORIG AP for EGATEN (TRICLABENDAZOLE)